Vera Therapeutics Quarterly Balance Sheets Chart
Quarterly
|
Annual
Vera Therapeutics Quarterly Balance Sheets Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| assets | ||||||||||||||||||
| current assets: | ||||||||||||||||||
| cash and cash equivalents | 49,121,000 | 55,090,000 | 92,646,000 | 27,256,000 | 25,085,000 | 69,105,000 | 45,681,000 | 27,441,000 | 137,385,000 | 43,459,000 | 30,475,000 | 50,427,000 | 111,506,000 | 79,674,000 | 86,191,000 | 91,625,000 | 49,505,000 | |
| marketable securities | 507,706,000 | 534,744,000 | 548,206,000 | 326,053,000 | 359,302,000 | 334,559,000 | 115,035,000 | 132,498,000 | 147,132,000 | 59,768,000 | 71,194,000 | 83,945,000 | 81,501,000 | 39,432,000 | ||||
| prepaid expenses and other assets, current | 14,527,000 | 16,242,000 | 10,366,000 | 10,822,000 | 10,360,000 | 12,706,000 | 11,307,000 | |||||||||||
| total current assets | 571,354,000 | 606,076,000 | 651,218,000 | 364,131,000 | 394,747,000 | 416,370,000 | 172,023,000 | 171,620,000 | 190,614,000 | 204,449,000 | 125,698,000 | 124,982,000 | 142,338,000 | 157,743,000 | 82,537,000 | 89,760,000 | 95,876,000 | 51,532,000 |
| property and equipment | 1,151,000 | 1,062,000 | 960,000 | 368,000 | 155,000 | 81,000 | 92,000 | 34,000 | 40,000 | 45,000 | 51,000 | 56,000 | 21,000 | 16,000 | ||||
| operating lease right-of-use assets | 2,471,000 | 2,915,000 | 3,372,000 | 3,921,000 | 1,929,000 | 2,432,000 | 2,949,000 | 3,481,000 | 4,030,000 | 4,594,000 | 5,173,000 | 5,768,000 | 5,724,000 | 6,275,000 | ||||
| prepaid expenses and other assets, noncurrent | 3,552,000 | 114,000 | 131,000 | 140,000 | 460,000 | 473,000 | 471,000 | |||||||||||
| total assets | 578,528,000 | 610,167,000 | 655,681,000 | 368,560,000 | 397,291,000 | 419,356,000 | 175,546,000 | 175,618,000 | 195,178,000 | 209,604,000 | 131,435,000 | 131,370,000 | 148,782,000 | 164,974,000 | 83,748,000 | 91,167,000 | 97,647,000 | 51,825,000 |
| liabilities and stockholders’ equity | ||||||||||||||||||
| current liabilities: | ||||||||||||||||||
| accounts payable | 13,157,000 | 9,262,000 | 7,665,000 | 4,602,000 | 4,664,000 | 5,209,000 | 11,118,000 | 12,300,000 | 13,280,000 | 5,326,000 | 11,991,000 | 7,012,000 | 7,084,000 | 7,328,000 | 1,385,000 | 964,000 | 1,723,000 | 1,440,000 |
| operating lease liabilities | 855,000 | 1,191,000 | 1,483,000 | 1,872,000 | 2,116,000 | 2,275,000 | 2,436,000 | 2,518,000 | 2,560,000 | 2,645,000 | 2,689,000 | 2,450,000 | 2,490,000 | |||||
| accrued expenses and other liabilities, current | 19,542,000 | 11,441,000 | 16,223,000 | 19,990,000 | 11,638,000 | 7,059,000 | 8,749,000 | |||||||||||
| total current liabilities | 33,554,000 | 21,894,000 | 25,371,000 | 26,464,000 | 18,418,000 | 14,543,000 | 22,303,000 | 24,621,000 | 26,835,000 | 23,529,000 | 25,600,000 | 15,920,000 | 17,279,000 | 19,969,000 | 7,690,000 | 4,042,000 | 3,771,000 | 3,753,000 |
| long-term debt | 74,464,000 | 50,908,000 | 50,687,000 | 50,470,000 | 50,263,000 | 50,066,000 | 49,877,000 | 25,042,000 | 24,962,000 | 24,886,000 | 24,810,000 | 4,966,000 | 4,952,000 | 4,937,000 | 4,923,000 | |||
| operating lease liabilities, noncurrent | 2,233,000 | 2,366,000 | 2,468,000 | 2,568,000 | 455,000 | 919,000 | 1,395,000 | 1,962,000 | 2,571,000 | 3,194,000 | 3,831,000 | 4,480,000 | 4,761,000 | 5,357,000 | ||||
| total liabilities | 110,251,000 | 75,168,000 | 78,526,000 | 79,502,000 | 69,422,000 | 65,814,000 | 73,861,000 | 51,911,000 | 54,655,000 | 51,895,000 | 54,527,000 | 25,652,000 | 27,278,000 | 30,549,000 | 14,156,000 | 5,690,000 | 5,492,000 | 5,565,000 |
| stockholders’ equity | ||||||||||||||||||
| preferred stock, 0.001 par value; 10,000,000 authorized as of june 30, 2025 and december 31, 2024; no shares issued and outstanding as of june 30, 2025 and december 31, 2024 | ||||||||||||||||||
| class a common stock | 64,000 | 64,000 | 64,000 | 55,000 | 55,000 | 54,000 | 44,000 | 44,000 | 44,000 | 44,000 | 28,000 | 28,000 | 27,000 | 27,000 | 21,000 | 21,000 | 21,000 | |
| additional paid-in capital | 1,057,161,000 | 1,047,225,000 | 1,037,948,000 | 705,784,000 | 699,457,000 | 691,146,000 | 410,492,000 | 407,185,000 | 403,964,000 | 400,850,000 | 290,216,000 | 286,642,000 | 277,623,000 | 275,551,000 | 193,627,000 | 192,665,000 | 191,732,000 | 2,845,000 |
| accumulated other comprehensive income | 527,000 | 654,000 | 393,000 | 1,044,000 | -450,000 | -173,000 | ||||||||||||
| accumulated deficit | -589,475,000 | -512,944,000 | -461,250,000 | -417,825,000 | -371,193,000 | -337,485,000 | -309,102,000 | -283,447,000 | -263,343,000 | -243,181,000 | -213,112,000 | -180,673,000 | -155,994,000 | -141,141,000 | -124,056,000 | -107,209,000 | -99,598,000 | -96,161,000 |
| total stockholders’ equity | 468,277,000 | 534,999,000 | 577,155,000 | 289,058,000 | 327,869,000 | 353,542,000 | 101,685,000 | 123,707,000 | 140,523,000 | 157,709,000 | 76,908,000 | 105,718,000 | 121,504,000 | 134,425,000 | 69,592,000 | 85,477,000 | 92,155,000 | |
| total liabilities and stockholders’ equity | 578,528,000 | 610,167,000 | 655,681,000 | 368,560,000 | 397,291,000 | 419,356,000 | 175,546,000 | 175,618,000 | 195,178,000 | 209,604,000 | 131,435,000 | 131,370,000 | 148,782,000 | 164,974,000 | ||||
| preferred stock, 0.001 par value; 10,000,000 authorized as of march 31, 2025 and december 31, 2024; no shares issued and outstanding as of march 31, 2025 and december 31, 2024 | ||||||||||||||||||
| accrued expenses and other liabilities, noncurrent | 286,000 | 286,000 | 286,000 | |||||||||||||||
| preferred stock, 0.001 par value; 10,000,000 authorized as of december 31, 2024 and 2023; no shares issued and outstanding as of december 31, 2024 and 2023 | ||||||||||||||||||
| preferred stock, 0.001 par value; 10,000,000 authorized as of september 30, 2024 and december 31, 2023; no shares issued and outstanding as of september 30, 2024 and december 31, 2023 | ||||||||||||||||||
| preferred stock, 0.001 par value; 10,000,000 authorized as of june 30, 2024 and december 31, 2023; no shares issued and outstanding as of june 30, 2024 and december 31, 2023 | ||||||||||||||||||
| preferred stock, 0.001 par value; 10,000,000 authorized as of march 31, 2024 and december 31, 2023; no shares issued and outstanding as of march 31, 2024 and december 31, 2023 | ||||||||||||||||||
| restricted cash, noncurrent | 293,000 | 293,000 | 293,000 | 293,000 | 293,000 | 293,000 | 293,000 | 293,000 | ||||||||||
| non-marketable equity securities | 11,000 | 13,000 | 29,000 | 57,000 | 58,000 | 122,000 | 324,000 | 580,000 | 867,000 | 1,114,000 | 1,478,000 | |||||||
| preferred stock, 0.001 par value; 10,000,000 authorized as of december 31, 2023 and december 31, 2022; no shares issued and outstanding as of december 31, 2023 and december 31, 2022 | ||||||||||||||||||
| accumulated other comprehensive gain | 251,000 | |||||||||||||||||
| prepaid expenses and other current assets | 11,681,000 | 9,593,000 | 7,296,000 | 10,562,000 | 10,410,000 | 6,805,000 | 3,569,000 | 4,201,000 | 1,977,000 | |||||||||
| prepaid expenses and other noncurrent assets | 470,000 | 465,000 | 166,000 | 149,000 | 82,000 | 67,000 | ||||||||||||
| accrued expenses and other current liabilities | 9,803,000 | 10,995,000 | 15,601,000 | 10,964,000 | 6,219,000 | 7,745,000 | 10,151,000 | 5,928,000 | 2,711,000 | 1,688,000 | 1,798,000 | |||||||
| accrued and other noncurrent liabilities | 286,000 | 287,000 | 286,000 | 286,000 | 286,000 | 286,000 | 286,000 | 286,000 | 286,000 | 286,000 | 286,000 | |||||||
| preferred stock, 0.001 par value; 10,000,000 authorized as of september 30, 2023 and december 31, 2022; no shares issued and outstanding as of september 30, 2023 and december 31, 2022 | ||||||||||||||||||
| accumulated other comprehensive loss | -75,000 | -142,000 | -4,000 | -224,000 | -279,000 | -152,000 | -12,000 | |||||||||||
| cash, cash equivalents and short-term marketable securities | 33,889,000 | |||||||||||||||||
| preferred stock, 0.001 par value; 10,000,000 authorized as of june 30, 2023 and december 31, 2022; no shares issued and outstanding as of june 30, 2023 and december 31, 2022 | ||||||||||||||||||
| restricted cash | 293,000 | |||||||||||||||||
| operating lease liabilities, current | 2,602,000 | |||||||||||||||||
| preferred stock, 0.001 par value; 10,000,000 authorized as of march 31, 2023 and december 31, 2022; no shares issued and outstanding as of march 31, 2023 and december 31, 2022 | ||||||||||||||||||
| prepaid expenses and other current assets, current | 11,045,000 | 2,863,000 | ||||||||||||||||
| prepaid expenses and other current assets, noncurrent | 162,000 | 51,000 | ||||||||||||||||
| restructuring liability, current | 377,000 | 367,000 | 360,000 | 515,000 | ||||||||||||||
| restructuring liability, noncurrent | 1,257,000 | 1,362,000 | 1,435,000 | 1,526,000 | ||||||||||||||
| preferred stock, 0.001 par value; 10,000,000 authorized as of december 30, 2022 and december 31, 2021; no shares issued and outstanding as of december 30, 2022 and december 31, 2021 | ||||||||||||||||||
| class b non-voting common stock, 0.001 par value; 14,600,000 shares authorized as of december 31, 2022 and december 31, 2021; 0 and 309,238 shares issued and outstanding as of december 31, 2022 and december 31, 2021, respectively. | ||||||||||||||||||
| restructuring liability | ||||||||||||||||||
| preferred stock, 0.001 par value; 10,000,000 authorized as of september 30, 2022 and december 31, 2021; no shares issued and outstanding as of september 30, 2022 and december 31, 2021 | ||||||||||||||||||
| class b non-voting common stock, 0.001 par value; 14,600,000 shares authorized as of september 30, 2022 and december 31, 2021; 0 and 309,238 shares issued and outstanding as of september 30, 2022 and december 31, 2021, respectively. | ||||||||||||||||||
| preferred stock, 0.001 par value; 10,000,000 authorized as of june 30, 2022 and december 31, 2021; no shares issued and outstanding as of june 30, 2022 and december 31, 2021 | ||||||||||||||||||
| class b non-voting common stock, 0.001 par value; 14,600,000 shares authorized as of june 30, 2022 and december 31, 2021; 99,238 and 309,238 shares issued and outstanding as of june 30, 2022 and december 31, 2021, respectively. | ||||||||||||||||||
| preferred stock, 0.001 par value; 10,000,000 authorized as of march 31, 2022 and december 31, 2021; no shares issued and outstanding as of march 31, 2022 and december 31, 2021 | ||||||||||||||||||
| class b non-voting common stock, 0.001 par value; 14,600,000 shares authorized as of march 31, 2022 and december 31, 2021; 309,238 shares issued and outstanding as of march 31, 2022 and december 31, 2021. | ||||||||||||||||||
| restricted cash, current | 50,000 | 50,000 | ||||||||||||||||
| liabilities, redeemable convertible preferred stock, and stockholders’ equity | ||||||||||||||||||
| commitments and contingencies | ||||||||||||||||||
| redeemable convertible preferred stock | 139,576,000 | |||||||||||||||||
| preferred stock, 0.001 par value; 10,000,000 and 0 shares authorized as of december 31, 2021 and 2020, respectively; no shares issued and outstanding as of december 31, 2021 and 2020 | ||||||||||||||||||
| class b non-voting common stock, 0.001 par value; 14,600,000 and 21,593,607 shares authorized as of december 31, 2021 and 2020, respectively; 309,238 and 0 shares issued and outstanding as of december 31, 2021 and 2020, respectively | ||||||||||||||||||
| total liabilities, redeemable convertible preferred stock, and stockholders’ equity | 83,748,000 | 91,167,000 | 97,647,000 | |||||||||||||||
| preferred stock, 0.001 par value; 10,000,000 and 0 shares authorized as of september 30, 2021 and december 31, 2020, respectively; no shares issued and outstanding as of september 30, 2021 and december 31, 2020 | ||||||||||||||||||
| class b non-voting common stock, 0.001 par value; 14,600,000 and 21,593,607 shares authorized as of september 30, 2021 and december 31, 2020, respectively; 309,238 and 0 shares issued and outstanding as of september 30, 2021 and december 31, 2020, respectively | ||||||||||||||||||
| preferred stock, 0.001 par value; 10,000,000 and 0 shares authorized as of june 30, 2021 and december 31, 2020, respectively; no shares issued and outstanding as of june 30, 2021 and december 31, 2020 | ||||||||||||||||||
| class b non-voting common stock, 0.001 par value; 14,600,000 and 21,593,607 shares authorized as of june 30, 2021 and december 31, 2020, respectively; 309,238 and 0 shares issued and outstanding as of june 30, 2021 and december 31, 2020, respectively | ||||||||||||||||||
| liabilities, redeemable convertible preferred stock, and stockholders’ deficit | ||||||||||||||||||
| stockholders’ deficit | ||||||||||||||||||
| class b non-voting common stock, 0.001 par value; 21,593,607 shares authorized as of march 31, 2021 and december 31, 2020; no shares issued and outstanding as of march 31, 2021 and december 31, 2020 | ||||||||||||||||||
| total stockholders’ deficit | -93,316,000 | |||||||||||||||||
| total liabilities, redeemable convertible preferred stock, and stockholders’ deficit | 51,825,000 | |||||||||||||||||
| operating expenses: | ||||||||||||||||||
| research and development | 2,932,000 | |||||||||||||||||
| general and administrative | 1,784,000 | |||||||||||||||||
| total operating expenses | 4,716,000 | |||||||||||||||||
| income from operations | -4,716,000 | |||||||||||||||||
| other income: | ||||||||||||||||||
| interest income | 2,000 | |||||||||||||||||
| interest expense | ||||||||||||||||||
| gain on issuance of convertible notes | ||||||||||||||||||
| change in fair value of convertible notes | ||||||||||||||||||
| total other income | 2,000 | |||||||||||||||||
| net income and comprehensive loss | -4,714,000 | |||||||||||||||||
| net income per share | -12,230 | |||||||||||||||||
| weighted-average common shares outstanding, basic and diluted | 385,401,000 |
We provide you with 20 years of balance sheets for Vera Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Vera Therapeutics. Explore the full financial landscape of Vera Therapeutics stock with our expertly curated balance sheets.
The information provided in this report about Vera Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.